LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive Biosciences today announced a partnership with ARUP Laboratories, a national reference laboratory and enterprise of the University of Utah, to offer the company’s molecular diagnostic bladder cancer tests to ARUP’s national network of clients.
Through a non-exclusive agreement, ARUP will offer Predictive’s CertNDxTM Bladder Cancer Assays in its comprehensive test menu to leading hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP’s clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory.
“We are excited to begin our partnership with ARUP, a laboratory that shares our passion for innovation and technology. We believe this alliance will greatly expand the availability of our bladder cancer products to a wider network of leading medical facilities that can benefit from CertNDx testing,” said Pierre Cassigneul, chief executive officer at Predictive Biosciences.
The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence post treatment. The test’s unique approach stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.
About Predictive Biosciences
Predictive Biosciences develops
novel molecular diagnostic cancer assays and provides molecular
pathology services for urology-based practices. Leveraging a portfolio
of patented biomarkers and clinical approaches, the company has built a
unique portfolio of assays for cancer management, first targeted at
bladder and prostate cancer. The company is backed by leading investors,
including Flybridge Capital Partners, Highland Capital Partners, Kaiser
Permanente Ventures, New Enterprises Associates, Inc. (NEA) and ProQuest
Investments. For additional information, please visit www.predictivebiosci.com.
About ARUP Laboratories
Founded in 1984, ARUP Laboratories
is a leading national reference laboratory and a nonprofit enterprise of
the University of Utah and its Department of Pathology. ARUP offers more
than 3,000 tests and test combinations, ranging from routine screening
tests to esoteric molecular and genetic assays. ARUP serves clients
across the United States, including many of the nation’s top university
teaching hospitals and children’s hospitals, as well as multihospital
groups, major commercial laboratories, group purchasing organizations,
military and other government facilities, and major clinics. In
addition, ARUP is a worldwide leader in innovative laboratory research
and development, led by the efforts of the ARUP Institute for Clinical
and Experimental Pathology®.